Quantitative interaction proteomics of neurodegenerative disease proteins by Hosp, Fabian et al.
                          Hosp, F., Vossfeldt, H., Heinig, M., Vasiljevic, D., Arumughan, A., Wyler,
E., ... Kehoe, P. (2015). Quantitative interaction proteomics of
neurodegenerative disease proteins. Cell Reports, 11(7), 1134-1146. DOI:
10.1016/j.celrep.2015.04.030
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.celrep.2015.04.030
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier (Cell) at
http://www.sciencedirect.com/science/article/pii/S2211124715004313. Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
Resource
Quantitative Interaction Proteomics of
Neurodegenerative Disease Proteins
Graphical Abstract
Highlights
d Quantitative interactomics of proteins involved in four
neurodegenerative diseases
d Differential interaction mapping of wild-type and disease-
associated proteins
d Interaction partners are significantly linked to disease
phenotypes in vivo
d Interaction of APP and LRPPRC appears to induce
mitochondrial dysfunction in AD
Authors
Fabian Hosp, Hannes Vossfeldt, ...,
Aaron Voigt, Matthias Selbach
Correspondence
matthias.selbach@mdc-berlin.de
In Brief
Hosp et al. show that quantitative
interaction proteomics of
neurodegenerative disease proteins
captures interactions relevant to
pathogenesis. Differential interactome
mapping reveals preferential binding of
the mitochondrial protein LRPPRC with
an early-onset Alzheimer’s disease (AD)
variant of APP, potentially contributing to
mitochondrial dysfunction observed in
AD.
Hosp et al., 2015, Cell Reports 11, 1134–1146
May 19, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.04.030
Cell Reports
Resource
Quantitative Interaction Proteomics
of Neurodegenerative Disease Proteins
Fabian Hosp,1,6 Hannes Vossfeldt,2 Matthias Heinig,1,3 Djordje Vasiljevic,1 Anup Arumughan,1 Emanuel Wyler,1
theGenetic andEnvironmental Risk forAlzheimer’sDisease (GERAD1)Consortium,Markus Landthaler,1Norbert Hubner,1
Erich E. Wanker,1 Lars Lannfelt,4 Martin Ingelsson,4 Maciej Lalowski,5 Aaron Voigt,2 and Matthias Selbach1,*
1Max Delbru¨ck Center for Molecular Medicine, Robert-Ro¨ssle-Straße 10, 13092 Berlin, Germany
2University Medical Center, RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany
3Max Planck Institute for Molecular Genetics, Ihnestraße 63-73, 14195 Berlin, Germany
4Uppsala University, Department of Public Health and Geriatrics, Uppsala University Hospital, Box, 609, 751 25 Uppsala, Sweden
5Biomedicum Helsinki, Meilahti Clinical Proteomics Core Facility and Folkha¨lsan Research Center, University of Helsinki, PO Box 63,
Haartmaninkatu 8, Helsinki 00014, Finland
6Present address: Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
*Correspondence: matthias.selbach@mdc-berlin.de
http://dx.doi.org/10.1016/j.celrep.2015.04.030
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
SUMMARY
Several proteins have been linked to neurodegenera-
tive disorders (NDDs), but their molecular function
is not completely understood. Here, we used quanti-
tative interaction proteomics to identify binding
partners of Amyloid beta precursor protein (APP)
and Presenilin-1 (PSEN1) for Alzheimer’s disease
(AD), Huntingtin (HTT) for Huntington’s disease,
Parkin (PARK2) for Parkinson’s disease, and Ataxin-1
(ATXN1) for spinocerebellar ataxia type 1. Our
network reveals common signatures of protein
degradation and misfolding and recapitulates known
biology. Toxicity modifier screens and comparison
to genome-wide association studies show that inter-
action partners are significantly linked to disease
phenotypes in vivo. Direct comparison of wild-type
proteins and disease-associated variants identified
binders involved in pathogenesis, highlighting the
value of differential interactome mapping. Finally, we
show that the mitochondrial protein LRPPRC inter-
acts preferentially with an early-onset AD variant of
APP.This interactionappears to inducemitochondrial
dysfunction, which is an early phenotype of AD.
INTRODUCTION
The functional characterization of disease-associated proteins is
a major challenge in the post-genomic era. Since proteins typi-
cally exert their function by binding other proteins, systematic
mapping of protein-protein interactions (PPIs) can help with the
understanding of protein function. The yeast two-hybrid (Y2H)
system generated large-scale human PPI networks (Rual et al.,
2005; Stelzl et al., 2005). Similarly, affinity purification and
mass spectrometry (AP-MS) has been employed to create inter-
actome maps for model organisms and humans (Ewing et al.,
2007; Gingras et al., 2007; Guruharsha et al., 2011; Malovannaya
et al., 2011). Although such interaction networks are still incom-
plete, they are beginning to provide valuable functional insights
for human diseases (Baraba´si et al., 2011; Ideker and Sharan,
2008; Vidal et al., 2011).
Since mutations might alter PPIs, comparing the interactions
of wild-type proteins and their disease-linked variants might be
particularly informative (Schuster-Bo¨ckler and Bateman, 2008;
Zhong et al., 2009). This information cannot be extracted from
most available interaction datasets. The Y2H assay is at best
semiquantitative and unable to detect small alterations in the af-
finity of PPIs (Estojak et al., 1995; Zhong et al., 2009). Similarly,
most AP-MS studies only used semiquantitative methods like
spectral counting or were performed entirely without quantifica-
tion. Spectral counting yields unreliable data, especially when
the interaction partner is of low abundance and/or the number
of samples is small (Gingras and Raught, 2012; Rinner et al.,
2007).
To overcome these problems, we sought to investigate PPIs of
disease-associated proteins in a quantitative manner. Quantita-
tive affinity purification and mass spectrometry (qAP-MS) can
accurately distinguish between specific interaction partners
and non-specific contaminants and quantify changes in PPIs
upon perturbation (Paul et al., 2011; Vermeulen et al., 2008;
Wepf et al., 2009). We reasoned that qAP-MS should be partic-
ularly well suited to identify interaction partners of disease-asso-
ciated proteins. Therefore, we employed this technology to
assess interaction partners of proteins involved in neurodegen-
erative diseases (NDDs). We focused on five well-known disease
proteins involved in Alzheimer’s disease (AD), Huntington’s dis-
ease (HD), Parkinson’s disease (PD), and spinocerebellar ataxia
type 1 (SCA1). These four NDDs are characterized by the accu-
mulation of protein aggregates in the brain and the progressive
loss of neurons (Ross and Poirier, 2004). HD and SCA1 are
caused by expansion of CAG repeats in the huntingtin and
ataxin-1 genes, respectively, which gives rise to proteins with
abnormally long polyglutamine (polyQ) tracts (Chung et al.,
1993; Rubinsztein et al., 1996). Although many risk factors
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contribute to prevalent cases of AD and PD, rare familial forms
have been identified that are caused by mutations in few genes
like APP, PSEN1/PSEN2, or PARK2 (Lin and Farrer, 2014; Tanzi
and Bertram, 2005).
Our quantitative proteomics data provide a comparative pro-
tein interaction network across several NDDs, revealing both
common modulators of several distinct disorders and disease-
specific pathogenic properties. We validated our interaction
data by co-immunoprecipitation (coIP) experiments and estab-
lished links to disease phenotypes in animal models and hu-
mans. Our screen identified leucine-rich pentatricopeptide
repeat motif containing protein (LRPPRC) as a preferential inter-
actor of Amyloid beta precursor protein (APP) carrying the
so-called Swedish mutation (APPsw), which causes early-onset
AD. LRPPRC is a key regulator of mitochondrial gene expres-
sion. Thus, the interaction might contribute to mitochondrial
dysfunction in AD.
RESULTS
Quantitative Interaction Screen for NDD Proteins
A fundamental challenge in biochemical screens for PPIs is the
trade-off between sensitivity and specificity. To address this
problem, we employed qAP-MS, in which the abundance of
proteins co-purifying with the bait is compared with a control
pull-down (Figure 1A). As an example, we show results from
experiments with Ataxin-1 (ATXN1). We first investigated pro-
teins specifically co-purifying with wild-type ATXN1 (normal
polyQ track length, ATXN1-Q30) relative to the empty vector
control in HEK293T cells. We identified 731 proteins, most of
which had a heavy to light (H/L) stable isotope labeling by
amino acids in cell culture (SILAC) ratio around 1 in both the
forward experiment and the corresponding label swap (Fig-
ure 1B). These proteins were therefore considered unspecific
contaminants (Figure S1A). ATXN1-Q30 itself had a high H/L
ratio in the forward experiment and an inverse ratio in the
reverse experiment, indicating efficient enrichment of the bait
protein. In addition, several 14-3-3 proteins specifically
co-purified with ATXN1-Q30 in both experiments (Figure S1B).
14-3-3 proteins are known interaction partners of wild-type and
mutant ATXN1 with a critical role in ATXN1-mediated neurode-
generation in vivo (Chen et al., 2003). 14-3-3 proteins bind to
ATXN1 phosphorylated on serine residue 776 by AKT (Chen
et al., 2003; Emamian et al., 2003), and our mass spectrometry
data showed that serine 776 is indeed phosphorylated (Fig-
ure S2). Another identified interaction partner was the tran-
scriptional repressor Capicua protein homolog (CIC). ATXN1
is known to interact with CIC in the mouse brain and to alter
its repressor activity (Lam et al., 2006). Collectively, these re-
sults indicate that our approach can identify functionally
relevant in vivo interaction partners, including phosphoryla-
tion-dependent ones. Since AP-MS can enrich entire com-
plexes, not all of these interaction partners are necessarily
direct binders of the bait protein.
Overall, we identified 50 potential interaction partners of
wild-type ATXN1. Several of these proteins are involved in
splicing (MBNL1, SF1, U2AF1, and U2AF2) and transcriptional
regulation (CIC, HDAC3, TBL1XR1, and MED27), consistent
with the nuclear function of ATXN1 (Lam et al., 2006). Other pro-
teins are involved in the ubiquitin proteasome system (PSMA4,
PSMB1, SKP1, and UBC), consistent with previous data (Choi
et al., 2007). Performing the same experiment with polyQ-
extended ATXN1, we identified a similar number of potential
interaction partners (Figures 1C and S1C). Of note, 80% of
the proteins were shared between the wild-type and disease-
associated forms (Table S1). This result suggests that (1) polyQ
expansion does not dramatically change the interaction partners
of ATXN1 (see below) and (2) the reproducibility of the data is
high.
Interaction Network of NDD Proteins
In total, we carried out qAP-MS screens for five different disease
proteins involved in four NDDs (AD, HD, PD, and SCA1). For each
protein, we used both the wild-type form and disease-associ-
ated variants, resulting in 12 different bait proteins (Figure S3A).
Altogether, we performed 72 pull-downs of tagged bait proteins
with corresponding empty vector controls. Every bait protein
was tested in at least four biological replicates (i.e., at least
two forward and two reverse experiments). Overall, the repro-
ducibility between replicates was high (mean correlation coeffi-
cient R = 0.83; Figure S3B). To further increase robustness, we
averaged over all forward and reverse experiments for each
bait protein. Proteins were considered specific interaction part-
ners when they (1) were enriched at least 2-fold on average
and (2) showed inverted SILAC ratios in the reverse experiments
(see the Supplemental Experimental Procedures for details). At
this stage, we did not distinguish between wild-type forms and
disease-associated variants but instead combined the data at
the level of the disease protein (Table S1). In total, 373 proteins
passed our cutoff criteria and were classified as interactors.
Ten proteins were detected as shared interaction partners
in at least three of the four diseases investigated (Figure 1D)
and are enriched in the Gene Ontology (GO) term proteolysis
(p < 3.5 3 104, Benjamini-Hochberg correction). This result is
consistent with the idea that the ubiquitin-proteasome system
andmolecular chaperones aremodulators of neurodegeneration
in several NDDs (Williams and Paulson, 2008). Interestingly,
however, most of the interactions were unique for a single dis-
ease. This was even the case for HD and SCA1, although both
diseases are caused by proteins with elongated polyQ tracts.
Hence, our data highlight considerable differences in disease
pathogenesis and/or the native cellular function of the respective
disease proteins.
Our NDD network contains several known interactions of bio-
logical relevance. For example, we observed binding of Preseni-
lin-1 (PSEN1) to the N-oligosaccharyl transferase complex (OSC)
(Lee et al., 2010) and the interaction of VCP with both Huntingtin
(HTT) and Parkin (PARK2) (Hirabayashi et al., 2001; Imai et al.,
2003). We also found that enriched GO terms of interaction part-
ners are largely consistent with the respective bait protein in
terms of localization and function (Figure 1E). Thus, our unbiased
interaction network recapitulates results from multiple studies,
strongly supporting the functional relevance of our data. On
the other hand, we failed to identify several well-described inter-
actions such as binding of APP and PSEN1 to the gamma-sec-
retase complex. This may be due to the transient nature of these
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Figure 1. Experimental Design and Global Properties of the qAP-MS Screen
(A) Stable isotope-labeled HEK293T cells are transiently transfected with plasmids encoding a control or bait protein with a single c-myc-tag. Immunoprecip-
itation of tagged constructs is followed by liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis. Crossover experiments are performed by
swapping the transfected plasmid constructs. See also Figure S1.
(B andC) Protein-protein interaction screen for empty vector control pull-down against (B) ATXN1-Q30 (wild-type) and (C) ATXN1-Q82 (mutant), including reverse
experiments. Specific interactors of ATXN1-Q30 or ATXN1-Q82, respectively, are marked in red. The position of the bait protein is indicated. See also Figure S2.
(D) A Venn diagram highlights unique and shared interactions between the bait proteins associated with different neurodegenerative diseases. See also Figures
S3 and S4.
(E) Gene Ontology analysis of identified interactors.
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interactions or other factors. For example, it has been reported
previously that the mature gamma-secretase complex can only
be purified when pull-downs are combined with lectin-based af-
finity chromatography (Kimberly et al., 2002; Yang et al., 2002).
Since most of our interactions are novel, we sought to validate
our data by independent experimental approaches. First, we
tested if western blotting could validate the interactions. In 18
out of 18 tested cases (selection based on antibody availability),
this confirmed our results (Figure S4A). Given that tagging,
overexpression, and/or using HEK293T cells could also lead to
false-positive interactions, we also performed coIP experiments
with the endogenous proteins in neuroblastoma cells. In nine out
of nine tested cases, these experiments validated the qAP-MS
results (Figure S4B). Collectively, these results indicate that our
qAP-MS screen detects PPIs with high specificity.
Interaction Partners of ATXN1 Are Relevant for
Neurodegeneration In Vivo
Next, we sought to investigate the link between identified PPIs
and NDD phenotypes in vivo. To this end, we employed a well-
established Drosophila melanogaster model for NDD to test the
relevance of identified ATXN1 interaction partners in vivo (Fer-
nandez-Funez et al., 2000). As expected, flies expressing human
ATXN1-Q82 in photoreceptor cells showed the characteristic,
so-called rough-eye phenotype (REP) indicative of neurodegen-
eration (Figures 2A–2C). We then asked if proteins, which we
identified as ATXN1-Q82 interaction partners, have an impact
on the REP by knocking them down in a tissue-specific manner
with small hairpin RNAs (shRNAs) (Dietzl et al., 2007). Of the 49
identified interaction partners of ATXN1-Q82, 24 had direct fly
orthologs, and 14 of those were available as non-sterile shRNA
strains. Silencing two of these genes affected eye morphology
alone, and the strains were therefore excluded. The remaining
12 strains were crossed with ATXN1-Q82 transgenic flies to
generate F1 flies that express ATXN1-Q82 and the respective
shRNA under the same eye-specific promoter. Strains were
classified according to the impact of the shRNA on the REP
(from 0 = no impact to +++ = lethal). Intriguingly, 9 of the 12 lines
exhibited a strong enhancement of the REP (++ or +++, Figures
2F and 2G; Table S2; Figure S5), including necrotic spots indic-
ative of neurodegeneration from subjacent photoreceptor neu-
rons (purple coloring, Figures 2F and 2G). In some cases, no
viable offspringwas obtained, suggesting a strong enhancement
of the neurodegeneration phenotype (Figure 2G). The high over-
lap between ATXN1 interaction partners and genetic modifiers of
ATXN1-mediated neurodegeneration strongly suggests that our
data are functionally relevant for NDD phenotypes. The 75% hit
rate is considerably higher than the typical hit rate in unbiased
genetic screens (1%–4%) (Fernandez-Funez et al., 2000; Kalten-
bach et al., 2007), whichmakes the overlap highly significant (p <
3.4 3 1010, hypergeometric test with an assumed hit rate of
5%). We also tested all 12 shRNA in another Drosophila model
expressing human tau protein (GMR_Tau[R406W]), which exhibit
a similar REP (Chatterjee et al., 2009). None of the 12 tested
shRNA lines showed an apparent REP change in this model.
Thus, the observed REP-modifying effects are specific for the
ATXN1-Q82 disease model (Table S2). Collectively, these exper-
iments show that our interaction partners are specifically rele-
vant for ATXN1-Q82-mediated neurodegeneration in vivo.
Interaction Partners of APP and PSEN1 Are Linked to
Human Disease Phenotypes
To investigate whether our identified interaction partners are also
linked to disease phenotypes in humans, we compared our inter-
action data for APP and PSEN1 with a genome-wide association
study (GWAS) for AD (Li et al., 2008). We used gene set enrich-
ment analysis of SNP data (Heinig et al., 2010; Holden et al.,
2008) to test if genes encoding APP and PSEN1 interaction part-
ners are also found as candidates in the AD GWAS data (Fig-
ure 3A; see Experimental Procedures for details). We found
that SNPs associated with interaction partners of wild-type
and mutant APP and mutant PSEN1 had significantly lower p
values than the global distribution of SNPs (Figures 3B and 3C;
Table S3; one-sided Wilcoxon-Mann-Whitney test). Thus, the in-
teractome of these proteins is significantly associated with dis-
ease, even though no single interaction partner alone showed
wild-type lacZ ATXN1-Q82
B C D E FA
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Figure 2. Disease-Modifying Effects of ATXN1 Interactors In Vivo
(A and B) Eye pictures of wild-type (A) and lacZ-expressing (B) Drosophila are shown as controls.
(C) Expression of ATXN1-Q82 in the fly compound eye induces a rough eye phenotype (REP).
(D–G) RNAi-mediated silencing of identified qAP-MS targets enhances the REP induced by ATXN1-Q82 expression (purple spots are necrotic lesions).
REP-modifying effect classification: 0, unchanged; +, mild enhancement; ++ strong enhancement; +++, lethal.
See also Figure S5 and Table S2.
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genome-wide significance in this GWAS. To validate these find-
ings, we went on and replicated this analysis with an indepen-
dent GWAS dataset based on a larger cohort (Harold et al.,
2009). We were able to replicate our findings for wild-type and
mutant APP (Figures 3B and 3C; Table S3). In summary, the
comparison with GWAS data suggests that our interaction
maps for APP and PSEN1 are functionally relevant for AD. This
corroborates the view that PPI data can help linking disease
genes and phenotypes (Lundby et al., 2014; Rossin et al., 2011).
Preferential Interactions of Wild-Type Proteins and
Disease-Associated Variants
Next, we asked if our approach could also identify differential
protein binding behavior between the wild-type form of a protein
and its disease-associated variant in the same pull-down exper-
iment. To this end, we directly compared interaction partners
of wild-type proteins and their disease-associated variants by
transfecting HEK293T cells with either the myc-tagged wild-
type bait proteins or their disease-associated variants (Figures
4A and S3A). Proteins were considered preferential binders
when they were enriched at least 1.4-fold on average and
showed an inverted ratio in the crossover experiment (Figure S6;
Experimental Procedures). While most proteins had abundance
ratios close to one, we found that several of our previously iden-
tified interactors indeed showed a preferential binding behavior
for one of the two offered bait protein variants (Figure 4B). In to-
tal, we identified 125 proteins with preferential binding behavior
with our qAP-MS approach (Table S1), including several already
known differential interactors. For instance, we observed
preferential binding of the Capicua homolog CIC toward the
ATXN1-Q30 wild-type when compared to the ATXN1-Q82
mutant variant, as previously reported (Lim et al., 2008). The
N-Cor/SMRT complex member HDAC3 showed the same
behavior, consistent with the finding that ATXN1 loss of function
contributes to transcriptional dysregulation (Crespo-Barreto
et al., 2010). We also observed that two members (DDOST and
RPN1) of the OST bound preferentially to wild-type PSEN1
compared to PSEN1-A431E. This interaction has recently been
shown to mediate glycosylation of the v-ATPase required for
lysosomal targeting, proteolysis, and autophagy, although it
was not known before that it is affected by the disease-associ-
ated mutation (Lee et al., 2010).
The APP Swedish Mutant K670N/M671L Binds LRPPRC
and Impairs Mitochondrial Function
To further validate our data, we selected one differential binding
partner for follow-up experiments. We focused on the interaction
between APP and LRPPRC. LRPPRC is a conserved nuclear
gene that encodes an RNA-binding protein that is imported
into mitochondria (Sterky et al., 2010). In the mitochondrial ma-
trix, LRPPRC post-transcriptionally regulates the expression of
mitochondrial genes (Gohil et al., 2010; Ruzzenente et al.,
2012; Sasarman et al., 2010). LRPPRC is therefore an essential
regulator of the mitochondrial respiratory chain. Intriguingly, mu-
tations in LRPPRC cause Leigh syndrome of the French-Cana-
dian type (LSFC), a NDD characterized by complex IV deficiency
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Figure 3. APP and PSEN1 Interactors Are Linked to Human Disease Phenotypes
(A) Gene set enrichment analysis workflow for qAP-MS targets of Alzheimer’s disease.
(B) Cumulative distribution function of the p values of SNPs associated with genes in the different subsets for the GenADA and the GERAD cohort.
(C) GSEA-SNP results for GenADA and GERAD cohorts. Interactors of mutant baits are significantly linked to disease. p values are based on a one-sided
Wilcoxon-Mann-Whitney test.
See also Table S3.
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(Mootha et al., 2003). Thus, LRPPRC is itself an NDD-associated
gene.
Our original screen identified LRPPRC as an interaction part-
ner of both wild-type APP and APP-K670N/M671L (Table S1).
In the direct comparison, LRPPRC co-purified preferentially
with the disease-associated form (Figure 5A; Table S1). The
K670N/M671L variant of APP is the so-called Swedish mutation
(APPsw), which causes excessive production of Ab and leads to
early-onset AD with highly elevated levels of oxidative stress
(Marques et al., 2003). Given that it is well established that mito-
chondrial function is impaired in AD (Querfurth and LaFerla,
2010), we hypothesized that the APP/LRPPRC interaction might
contribute to mitochondrial dysfunction.
First, we used co-immunoprecipitation to confirm that the
amount of LRPPRC that co-purified with APP was slightly higher
for the Swedish variant (Figure 5B). Conversely, when we immu-
noprecipitated LRPPRC, we detected more APPsw than wild-
type APP in the precipitate. Thus, the preferential binding
observed by qAP-MS could be validated by reciprocal coIPs.
We also found that endogenous (i.e., wild-type) APP and
LRPPRC interact in neuroblastoma cells (Figure S4B). Second,
in order to assess the differential binding behavior with an inde-
pendent method, we used the proximity ligation assay (PLA).
PLA detects endogenous protein complexes in situ using anti-
body-linked oligonucleotides (So¨derberg et al., 2006). We found
that endogenous APP and LRPPRC co-localized in HEK293T
cells (Figure 6C, upper panels). Moreover, transfecting APPsw,
but not wild-type APP, significantly increased the signal
compared to the empty vector control (Figures 5C, lower panels,
and 5D). We also found that a small interfering RNA (siRNA)
against LRPPRC significantly reduced the signal, which vali-
dates the specificity of the assay. PLA experiments also showed
co-localization of endogenous APP and LRPPRC in neuroblas-
toma cells (Figure S7). Next, to investigate the relationship
between LRPPRC and APP in the human brain, we performed
immunohistochemistry in postmortem cortical brain slices of a
patient with early-onset AD caused by APPsw and age-matched
controls (Figure 5E). We found that APP and LRPPRC are co-ex-
pressed in cortical neurons of healthy controls with an overall
similar staining pattern, although these data cannot be used to
infer co-localization. Importantly, no LRPPRC staining was
observed in the Ab-positive amyloid plaques in AD patients.
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Thus, the protein does not appear to interact with Ab in the extra-
cellular aggregates in affected brain regions. In summary, these
data confirm the specific interaction between LRPPRC and APP
and the preferential interaction with the Swedish mutant. The
observation that LRPPRC is not a component of amyloid plaques
in AD patients suggests that the interaction occurs with intracel-
lular APP and not with extracellular Ab.
Mature LRPPRC is considered to be exclusively located in the
mitochondrial matrix (Sterky et al., 2010). While APP is mainly
thought to be associated with the plasma membrane and the
ER, it is also recruited to mitochondria via a cryptic targeting
sequence (Devi and Anandatheerthavarada, 2010; Devi et al.,
2006; Keil et al., 2004; Lin and Beal, 2006; Park et al., 2006).
Mitochondrial APP is not completely imported into the organelle
but remains associated with mitochondrial translocases such as
TOMM40. Consistently, we also identified TOMM40 and other
mitochondrial membrane proteins as APP interactors (Figure 1E;
Table S1). The topology of APP in mitochondria is such that its N
terminus is located in the matrix while the C terminus faces the
cytoplasm (Anandatheerthavarada et al., 2003; Devi et al.,
2006). Given the topology of mitochondria-associated APP, the
interaction with LRPPRC should occur via the matrix-exposed
N terminus. To investigate this possibility, we tested the interac-
tion of LRPPRC with an N-terminal truncation (Figure 5F).
LRPPRC co-purified with full-length APP (APP770), but not
with APPDN. These findings suggest that LRPPRC binds to the
mitochondrial matrix-exposed N terminus of APP.
Given that LRPPRC is a central regulator ofmitochondrial gene
expression,weaskedhowAPPswaffects theproteome.We tran-
siently transfected differentially SILAC-labeled cells with APP or
APPsw for 48 hr. Quantitative proteomics revealed that APPsw
markedly (3-fold) downregulated the cellular levels of LRPPRC
itself and its binding partner, SLIRP (Figure 6A). It is remarkable
that these proteins were among the most strongly regulated
ones in our unbiased experiment. Additionally, several members
of the cytochrome c oxidase or the NADH dehydrogenase com-
plexes were downregulated (Figure 6A). Thus, APPsw mediates
downregulation of LRPPRC and its downstream targets. We
speculated that the reduced expression of respiratory chain
components may be due to the downregulation of LRPPRC.
Therefore, we tested whether overexpressing LRPPRC together
withAPPswmight rescue its impact onmitochondria. Indeed, co-
expression of LRPPRC together with APPsw resulted in almost-
APPwt expression levels of LRPPRC/SLIRP and reduced the
impact on the downstream targets (Figure 6B). To further charac-
terize the relationship of APP, LRPPRC, and expression of respi-
ratory chain components,weanalyzedmRNA levels byqRT-PCR
(Figure 6C). Thesedata showed thatAPPswsignificantly downre-
gulates mRNA levels of LRPPRC and the respiratory chain mem-
berCOX1, a primary downstream target of LRPPRC. In summary,
these data show that APPsw downregulates expression of
LRPPRC and respiratory chain genes, and that the impact of
APPsw on respiratory chain proteins can partially be rescued
by LRPPRC overexpression.
Finally, in order to test whether these results are relevant for
mitochondrial function, we transiently transfected cells with
either APP wild-type or APPsw constructs and co-transfected
either LRPPRC or a siRNA directed against LRPPRC. We
measured aconitase activity as an enzymatic readout for oxida-
tive stress and overall mitochondrial function (Gardner, 2002).
Co-expression of LRPPRC increased the aconitase activity in
all conditions, while LRPPRC knockdown considerably reduced
the enzymatic activity (Figure 6D). This is consistent with the
essential role of LRPPRC for mitochondrial function (Ruzzenente
et al., 2012). Cells expressing APPsw showed a significant
(p < 0.005) decrease in aconitase activity when compared to
APP wild-type-expressing cells. Again, LRPPRC co-expression
partially restored aconitase activity to almost wild-type levels.
These findings suggest that LRPPRC levels might play an impor-
tant role in APPsw-induced stress phenotypes.
DISCUSSION
The premise of network medicine is that health and disease de-
pends on complex interactions between the different molecular
components of human cells (Baraba´si et al., 2011). Here, we
used qAP-MS to obtain the first quantitative PPI network for
several protein variants associated with different NDDs. Several
observations indicate that our data are of high quality and impor-
tant for pathogenesis. First, we recovered several known interac-
tions that have been shown to be relevant for NDDs. Second, we
confirmed 18 out of 18 novel interactions by co-immunoprecip-
itation in transiently transfected HEK cells and nine out of nine
endogenous interactions in neuroblastoma cells. Third, we find
that 75% of the identified interaction partners for ATXN1 are
functionally relevant for neurodegeneration in a fly model, similar
Figure 5. LRPPRC Preferentially Binds the APP Swedish Mutant K670N/M671L
(A) MS spectrum showing light and heavy (white and black circles) isotope clusters of a LRPPRC-derived peptide in the forward and reverse experiments.
(B) Reciprocal co-immunoprecipitation of APP and LRPPRC after transfection of APP variants in HEK293T cells. The APPsw mutation (K670N/M671L) co-
precipitates stronger with LRPPRC and vice versa, compared to APP wild-type.
(C) Proximity ligation assay (PLA) in non-transfected or transfected HEK293T cells: (a) positive control for SFPQ and NONO; (b) negative control without primary
antibodies; (c) negative control without primary antibody for LRPPRC; (d) staining for endogenous levels of APP and LRPPRC; (e) siRNA-mediated knockdown of
LRPPRC; (f) cells transfected with empty vector; (g) cells transfected with APP-WT; (h) cells transfected with APPsw. Scale bars, 25 mm. See also Figure S7.
(D) Quantification of PLA results from (C) (mean + SD; n = 3; *p < 0.05; **p < 0.005; >50 cells counted per experiment), two-tailed Student’s t test.
(E) Upper panel: immunodetection of LRPPRC in healthy aged-matched frontal cortex. Distinct granular immunostaining in neuronal cells along the cortical region
is detected. Arrows in the higher magnifications from the same areas point to vesicular-like structures in the cytoplasm (black arrows) and in the neuronal
processes (open arrows), similarly as for APP. Scale bar in upper panel is 500 mm and 200 mm in the magnified insets. Lower panel: immunodetection of Abeta
plaques in the ADsw temporal cortex. Plaque peripheries are immunodecorated by anti-APP staining (black arrows), while anti-LRPPRC staining was negative.
Scale bars represent 500 mm and 100 mm, respectively.
(F) LRPPRC co-purifies with APP splice-isoforms (APP770, APP695) and a C-terminal APP truncation (APP305) but not with an N-terminal APP truncation
(APPDN).
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to previous observations for HTT (Kaltenbach et al., 2007).
Fourth, we observe that interaction partners of APP and
PSEN1 are significantly enriched in AD-associated SNPs.
Collectively, these findings indicate that our network of mostly
novel interactions is a rich and valuable resource for the commu-
nity and may help us to better understand the molecular mecha-
nisms of NDDs.
Although the high validation rate shows the power of our
screen, it is also important to keep the limitations in mind.
Most importantly, we analyzed interactions of overexpressed
proteins in human cell lines. Although this setup is arguably
closer to the in vivo situation than the Y2H system, it cannot reca-
pitulate all relevant processes in human neurons. Moreover, in-
teractions might be lost during affinity purification or could be
impaired by the tag. We also cannot rule out that overexpression
of a disease-related protein might induce upregulation of spe-
cific proteins, which might therefore be misidentified as specific
interaction partners.
It has been argued that interaction maps are most informative
when they reflect differences between states such as health and
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Figure 6. The LRPPRC/APPsw Interaction Impairs Mitochondrial Function
(A and B) SILAC-based LC-MS/MS analysis reveals global proteome changes in HEK293T cells 48 hr post transfection. Heights of the yellow bars were multiplied
by ten for better visibility. (A) LRPPRC and SLIRP (marked in red) as well as downstream targets (mitochondrial complex I and IVmembersmarked in yellow) show
reduced expression after APPsw transfection compared to cells expressing APP wild-type. (B) Co-expression of LRPPRC together with APPsw results in almost
APP wild-type expression levels.
(C) mRNA levels of LRPPRC and its downstream target COX1 are reduced in APPsw-expressing cells as measured by qRT-PCR; mean + SD, n = 5, ***p < 0.0005;
*p < 0.05, two-tailed Student’s t test.
(D) Aconitase activity assay in transfected HEK293T cells; mean + SD; n = 4; **p < 0.005.
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disease (Ideker and Sharan, 2008). While the Y2H system and
standard AP-MS experiments can, in principle, identify interac-
tion partners of mutant proteins, the non-quantitative nature of
thesemethodsmakes it difficult to directly assess which interac-
tions are affected by the mutation. We used SILAC-based quan-
tification to directly compare the interactions of wild-type
proteins and their disease-associated variants for the first time
across several different NDDs. We found that for most proteins,
disease-associated mutations affected only a small subset of
specific PPIs.We also observed that this subset contains several
proteins with a known role in pathogenesis. This suggests that
differential binding partners may indeed be particularly informa-
tive for disease mechanisms.
Mitochondrial dysfunction is one of the earliest markers of AD
(Querfurth and LaFerla, 2010). While the role of Ab in this process
is well established, our finding that the mitochondrial matrix
protein LRPPRC interacts with APP provides evidence that mito-
chondria-associated APP might also play a role. It has been
shown that full-length APP associates with mitochondrial mem-
branes in an N (in mitochondria) to C (out cytoplasm) orientation
(Devi et al., 2006). We find that an N-terminal fragment of APP is
required for the interaction with LRPPRC, suggesting that the
interaction occurs via the matrix-exposed N terminus. It is not
yet clear how the Swedish mutation in the C terminus can affect
the interaction of the N terminus with LRPPRC. One possibility is
that the mutation enhances mitochondrial import and thus the
amount of APP accessible for the interaction. LRPPRC is a cen-
tral regulator of mitochondrial gene expression required for the
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Figure 7. Hypothetical Model for Mitochon-
drial Impairments Caused by APPsw and
LRPPRC
APP associates with mitochondria in an amino-
terminus-in/carboxy-terminus-out position. In
APP wild-type-expressing cells, LRPPRC in-
teracts with the APP N terminus. The free re-
maining LRPPRC pool can fulfill its regular function
preserving mitochondrial fidelity. In cells express-
ing APPsw, the pool of free LRPPRC is reduced via
its enhanced binding to APPsw. Thus, overall
levels of LRPPRC and downstream targets are
reduced and impair mitochondrial function.
coordinated translation of mitochondrial
mRNAs (Ruzzenente et al., 2012). It is
intriguing that mutations in LRPPRC
cause neurodegeneration in LSFC (Moo-
tha et al., 2003). We therefore speculate
that binding of APPsw to LRPPRC im-
pairs mitochondrial gene expression (Fig-
ure 7). The Swedish mutation enhances
both Ab production and binding to
LRPPRC. Thus, it is not straightforward
to separate both effects from each other.
Our observation that APPsw-induced
mitochondrial stress is partially rescued
by overexpressing LRPPRC indicates
that both factors play a role. Since
LRPPRC also associates with endogenous (i.e., wild-type)
APP, the interaction may also be relevant for sporadic AD cases
and/or for the normal cellular function of APP.
Genetic linkage analysis has identified many genes related to
inherited diseases, and the recent advance of sequencing tech-
nologies dramatically accelerated this process. Compared to the
pace of disease-gene discovery, their functional characterization
is lagging behind. This study shows that quantitative interaction
proteomics of disease proteins captures many aspects relevant
for pathogenesis. Systematic mapping of changes in PPIs might
thus help bridging the gap between identification of disease-
associated variants and disease phenotypes. The approach is
generic and can thus be applied to other diseases. Eventually,
differential interaction proteomics might open new avenues
toward individualized therapy.
EXPERIMENTAL PROCEDURES
Cell Culture
HumanHEK293T cellswere cultured and stable-isotope labeled under standard
conditions (see theSupplementalExperimental Procedures). Transient transfec-
tions of 15 mg myc-tagged expression vectors were performed with 30 mg poly-
ethylenimine transfection agent per 23 107 cells. Cellswere lysed inRIPAbuffer
supplemented with complete protease inhibitor (Roche) and 1% Benzonase
(Merck), and cell debris was cleared by centrifugation at 13,0003 g for 10 min.
Pull-Down Experiments
Immunoprecipitations of myc-tagged bait proteins were performed using the
mMACS c-myc isolation Kit (Miltenyi Biotec) according to the manufacturer’s
instructions. Proteins bound to the beads were eluted with 100 mM glycine
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(pH 2.5) and ethanol-precipitated overnight at 4C. Precipitated proteins were
processed essentially as described previously (Paul et al., 2011). Co-immuno-
precipitations of endogenous proteins were performed by crosslinking specific
anti-bait antibodies to NHS-activated Sepharose as described (Paul et al.,
2011). Co-precipitates were eluted by boiling in SDS loading buffer and subse-
quently analyzed by western blotting.
Drosophila Models and Genetic Screen
Flies were raised and maintained at 25C on standard food. The screening
stock was generated by recombination of GMR-GAL4 driver and UAS-
ATXN1-Q82 insertion (GMR > ATXN1-Q82). Screening itself was essentially
conducted as described previously (Vossfeldt et al., 2012).
Reporter Assays
For mitochondrial activity tests, mitochondria were isolated from 104–105
HEK293T cells using the mitochondria isolation kit (Miltenyi Biotec) according
to the manufacturer’s instructions. Mitochondrial activity was then assessed
by determining the mitochondrial aconitase activity (Aconitase Activity Assay
Kit, Merck) according to the manufacturer’s instructions. Values were normal-
ized to the mitochondrial protein concentration.
Liquid Chromatography Tandem Mass Spectrometry Analysis
Pull-down samples were measured on LTQ-Orbitrap or LTQ-Orbitrap XLmass
spectrometers and whole-proteome experiments on LTQ-Orbitrap Velos ma-
chines. Rawmass spectrometric datawere analyzed using theMaxQuant soft-
ware environment (Cox and Mann, 2008). See the Supplemental Experimental
Procedures for details.
GWAS Enrichment Analysis
Cohort data were acquired from two large GWASs with 753/736 cases/con-
trols (GenADA; Li et al., 2008) and 3,941/7,848 cases/controls (GERAD; Harold
et al., 2009). Genomic coordinates of all genes were obtained from BioMart
(Ensembl release 54). SNP coordinates (NCBI36 assembly) and association
summary statistics of the GenADA study were obtained from dbGAP (acces-
sion number phs000219v1). The same data structure for the GERAD study
was kindly provided by the authors. For each bait protein SNP, sets were
defined that comprise all SNPs that are located within a distance of 100 kb
of any gene whose protein interacts with the corresponding bait protein. A
one-sided Wilcoxon-Mann-Whitney test was applied in order to detect differ-
ences of the means of the distribution of GWAS p values within a SNP set
compared to the global distribution of p values (Heinig et al., 2010). Combined
p values were computed using Fisher’s method.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.04.030.
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